Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib plus reduced-intensity allogeneic hematopoietic stem cell transplantation versus imatinib alone in young patients with chronic-phase chronic myeloid leukemia
ChiCTR-ONRC-12002956Phase 4Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Overall survival and Progression-free survival. Started Jan 2004; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR-ONRC-12002956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-12002956.